Journal of Osteoporosis [17] D. Gallagher, D. Belmonte, P. Deurenberg et al., “Organ-tissue mass measurement allows modeling of ree and metabolically active tissue mass,” American Journal of Physiology, vol. 275, no. 2, pp. E249–E258, 1998. [18] M. P. Warren, “Endocrine manifestations of eating disorders ,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 333–343, 2011. [19] C. M. Gordon, E. Goodman, S. J. Emans et al., “Physiologic regulators of bone turnover in young women with anorexia nervosa,” Journal of Pediatrics, vol. 141, no. 1, pp. 64–70, 2002. [20] A. Caillot-Augusseau, M. H. Lafage-Proust, P. Margaillan et al., “Weight gain reverses bone turnover and restores circadian variation of bone resorption in anorexic patients,” Clinical Endocrinology, vol. 52, no. 1, pp. 113–121, 2000. [21] M. P. Warren, J. Brooks-Gunn, R. P. Fox et al., “Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study,” Fertility and Sterility, vol. 80, no. 2, pp. 398–404, 2003. [22] I. Legroux-Gerot, J. Vignau, F. Collier, and B. Cortet, “Factors inﬂuencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the eﬀect of hormone replacement therapy,” Calciﬁed Tissue International, vol. 83, no. 5, pp. 315–323, 2008. [23] C. K. Welt, J. L. Chan, J. Bullen et al., “Recombinant human leptin in women with hypothalamic amenorrhea,” New Eng- land Journal of Medicine, vol. 351, no. 10, pp. 987–997, 2004. [24] T. Thomas, F. Gori, S. Khosla, M. D. Jensen, B. Burguera, and B. L. Riggs, “Leptin acts on human marrow stromal cells to enhance diﬀerentiation to osteoblasts and to inhibit diﬀeren- tiation to adipocytes,” Endocrinology, vol. 140, no. 4, pp. 1630– 1638, 1999. [25] J. E. Mitchell and S. Crow, “Medical complications of anorexia nervosa and bulimia nervosa,” Current Opinion in Psychiatry, vol. 19, no. 4, pp. 438–443, 2006. 7